Enrollment in all ongoing Depatux-M studies has been halted for newly diagnosed glioblastoma due to lack of survival benefit.
Researchers have reported that individuals undergoing CAR T-cell therapy for blood cancers are at risk of neurological side effects; categorizing and understanding these side effects could be important in future diagnosis and treatment.
We had the pleasure of speaking with Manmeet Ahluwalia about current vaccine options for glioblastoma, including a survivin vaccine (SurVaxM) for newly diagnosed glioblastoma.
Researchers have discovered administering pembrolizumab before surgery is more effective for the treatment of recurrent glioblastoma, than when administering the drug afterwards.
Take a look behind the scenes of a recent CNS Oncology paper as we ask the authors about the Nativis Voyager® for the treatment of glioblastoma.
A 15-year-old boy, who has a rare brain tumor, is about to become one of the first UK patients to receive proton-beam therapy.
New research has revealed that gliomas in neurofibromatosis type 1 (NF1) patients may be effectively treated by immunotherapy.
In this interview, we spoke with Justin Lathia about sexual dimorphism in glioblastoma, including his talk on sex differences in microglia and the glioma microenvironment.
This week we look at NurOwn® for multiple sclerosis, a combination therapy failing to meet primary endpoint for glioblastoma and warnings from the US FDA.
A combination of CBL0137 and panobinostat has been demonstrated to effectively treat neuroblastoma in mice. This combination therapy has the potential to lead the fight against this aggressive childhood cancer.